알지노믹스

476830KOSDAQ자연과학 및 공학 연구개발업

57.5 / 100

Reference Date: 2026-06-10

Financial Score23.5 / 40

News Sentiment20.0 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Operating Profit metrics are weak. Plunged 42.0% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Aljonoomics is a biotech company that develops new drugs using platform technology, leveraging RNA trans-splicing ribozyme to target and replace specific RNA sequences with therapeutic genes. The company generates revenue through technology licensing and focuses on developing gene therapy treatments for genetic diseases and cancer, including hepatocellular carcinoma.

Number of Employees

39people

Average Salary

193.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 62.704.0Point

PBR

—Industry Average 3.243.5Point

ROE

—Industry Average -32.093.5Point

Debt Ratio

1.62Industry Average 7.318.0Point

Half of industry avg (excellent)

Trend 2023~20254.5 / 10 points

Revenue Growth Rate

1.5 / 3

Operating Profit Growth Rate

1.0 / 3

Avg ▲1.8% (2-year basis)

ROE Trend

2.0 / 4

Detailed News Sentiment

11 totalPositive 9Neutral 1Negative 1Average Sentiment Score 80

Positive
'빅파마 10조원 베팅한 인비보 CAR-T'...알지노믹스가 주목받는 ...
알지노믹스의 인비보 CAR-T 기술이 글로벌 빅파마로부터 대규모 투자를 유치하며 주목받고 있다.
Negative
[월간 ETF] UNICORN 포스트IPO액티브, 새내기株의 '쓴맛'
알지노믹스 ETF의 포스트IPO액티브 가격이 한 달 만에 30% 이상 하락하며 저조한 수익률을 기록, 부정적 영향 예상.
Positive
릴리 인수 뒤 암환자 임상반응률 100%…'인 비보 CAR-T' 기대감...
릴리의 CAR-T 치료제 'KLN-1010' 임상 1상에서 암환자 반응률이 100%를 기록하며 긍정적인 초기 결과를 보여주고 있어, 국내 관련 기업들의 관심이 증가하고 있다.

Detailed Momentum

52-week position1.0Point

Near 52w low (2%, downtrend)

Current 93,900Won52-week high 236,00052-week low 90,000

1-month return0.0Point

1m -41.97% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral주식등의대량보유상황보고서(약식)2026-06-09
Neutral분기보고서 (2026.03)2026-05-15